CD155, also known as poliovirus receptor or PVR, is a cell-surface adhesion and signaling protein whose role in cancer is more complex than its name might suggest. In healthy tissues, CD155 participates in interactions between cells and can help regulate immune communication. In many tumors, however, its abundance is increased. The protein can bind receptors on immune cells, including the activating receptor DNAM-1 and inhibitory receptors such as TIGIT and CD96. The balance among these interactions influences whether an NK cell becomes activated, releases toxic granules, and kills a target—or receives signals that restrain its response. A tumor that maintains high levels of CD155 can therefore alter the molecular conversation at the immune synapse.

The new research focuses on what happens to CD155 after it has been produced by a cancer cell. N-glycosylation occurs when carbohydrate chains are enzymatically attached to specific asparagine residues as a protein moves through the endoplasmic reticulum and Golgi apparatus. This modification can affect a protein’s folding, trafficking, half-life, and ability to interact with other molecules. It is not simply a decorative coating. For membrane proteins, glycosylation can determine whether they reach the cell surface, how long they remain there, and whether they are protected from degradation. In the case of CD155, the study links this sugar-based processing to greater protein stability, creating a more persistent immune-evasion signal on colorectal cancer cells.

That connection is important because the amount of a protein inside a tumor cell does not necessarily predict its impact on immunity. A molecule may be synthesized in large quantities but rapidly removed from the cell surface, limiting its ability to contact immune receptors. Conversely, a stabilized membrane protein can continuously engage immune cells in the tumor microenvironment. By supporting CD155’s persistence, N-glycosylation may extend the period during which cancer cells can deliver inhibitory signals to NK cells. The result is a potential molecular shield: not an invisible tumor, but one that is better equipped to dampen the attack once immune cells arrive.

NK cells are particularly relevant to this process because they do not require the same antigen-specific priming as conventional cytotoxic T cells. They survey tissues for patterns associated with cellular stress, infection, or malignant transformation. When activated, they form an immune synapse with a target cell and release perforin and granzymes, proteins that initiate target-cell death. They also produce cytokines such as interferon-gamma, which can shape broader antitumor responses. Tumors survive when they prevent this sequence from beginning, disrupt the immune synapse, or suppress the signals that trigger cytotoxicity. Persistent CD155 may contribute to that suppression by favoring inhibitory receptor engagement over activating signals.

The study’s central implication is that the glycosylation machinery of a tumor cell may be as relevant to immune escape as the immune checkpoints themselves. Cancer therapies have traditionally concentrated on blocking receptors or ligands that restrain immune cells. The reported mechanism suggests another point of intervention upstream: preventing CD155 from being correctly processed, transported, or maintained at the cell surface. In principle, disrupting the relevant glycosylation sites or the enzymes that install N-glycans could make CD155 less stable and more vulnerable to turnover. Such an approach would need to be carefully designed, because glycosylation controls thousands of proteins in normal cells and broad interference could cause substantial toxicity.

The findings also raise the possibility of combining strategies that target CD155 biology with existing immunotherapies. If glycosylation-dependent stabilization keeps CD155 abundant, blocking an inhibitory receptor such as TIGIT might be more effective when the ligand is simultaneously reduced or destabilized. Alternatively, therapies aimed at tumor-specific glycosylation patterns could expose colorectal cancer cells to stronger NK-cell pressure while limiting effects on healthy tissues. These ideas remain dependent on the precise experimental evidence, clinical context, and safety profile of any proposed intervention. A mechanism identified in cultured cells or experimental models must still be validated in patient tumors, where oxygen levels, nutrient availability, stromal cells, macrophages, and treatment history can all reshape glycosylation and immune behavior.

Colorectal tumors are biologically diverse, and CD155 regulation may not be uniform across patients. Genetic alterations, inflammatory signals, metabolic conditions, and the composition of the tumor microenvironment can influence both glycosyltransferase activity and immune-cell function. Some cancers may rely heavily on glycosylation to preserve CD155, whereas others may use additional pathways to suppress NK cells. This variability makes CD155 glycosylation potentially valuable not only as a therapeutic target but also as a biomarker. Measuring CD155 abundance, its glycan status, or the expression of relevant glycosylation enzymes could eventually help identify tumors with a particularly strong CD155-mediated immune-evasion program.

The report adds to a growing view of cancer as an ecosystem in which molecular modifications determine who can communicate with whom—and with what consequences. Glycosylation is increasingly recognized as a major regulator of tumor progression, affecting receptors, transporters, adhesion molecules, and immune checkpoints. By connecting this biochemical layer to CD155 stability and NK-cell surveillance, the study highlights how a seemingly small change in protein processing can have system-wide consequences for immune recognition. The discovery does not mean that a single sugar structure explains colorectal cancer’s resistance to immunity, but it identifies a potentially actionable link between tumor-cell metabolism, surface-protein stability, and immune escape.

For patients, the significance of the findings will ultimately depend on whether this pathway can be manipulated selectively and safely. The next steps will likely include defining the exact N-glycosylation sites that control CD155 stability, identifying the enzymes responsible, testing whether disrupting the modification restores NK-cell killing, and determining how the pathway behaves in human colorectal cancer samples. Researchers will also need to establish whether the mechanism affects other immune cells or interacts with chemotherapy, targeted drugs, and checkpoint inhibitors. If those questions are answered, the sugar coating that helps colorectal cancer preserve CD155 could become more than a molecular curiosity: it could represent a new vulnerability in tumors that have learned to survive under immune surveillance.

Subject of Research: N-glycosylation-mediated stabilization of CD155 and immune evasion by colorectal cancer cells

Article Title: N-glycosylation stabilizes CD155 to evade NK cell surveillance in colorectal cancer

Article References: Xu, J., Zhang, D., Yang, K. et al. “N-glycosylation stabilizes CD155 to evade NK cell surveillance in colorectal cancer.” Cell Death Discovery (2026). https://doi.org/10.1038/s41420-026-03302-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03302-9

Keywords: colorectal cancer, CD155, N-glycosylation, natural killer cells, immune evasion, tumor immunology, glycosylation, cancer therapy

The immune system’s role in combating cancer is complex and often paradoxical. While immune cells typically detect and destroy malignant cells, tumors have evolved sophisticated strategies to manipulate immune components to their advantage. Among these, B cells—traditionally recognized for their antibody-producing capability—have recently emerged as pivotal players in tumor immunology, capable of assuming diverse phenotypes and functions under pathological conditions. The discovery that pancreatic cancer can inhibit Pax5 to rewire B cell lineage commitment adds a new layer of understanding to how tumors achieve sustained immunosuppression.

Pax5 serves as a master regulator of B cell development, enforcing lineage fidelity by ensuring that progenitor cells fully commit to the B cell fate and preventing transdifferentiation into other hematopoietic lineages. The study’s detailed molecular analyses showed that pancreatic tumors trigger a downregulation of Pax5 within infiltrating B cells. This downregulation results in a remarkable plasticity that allows these cells to adopt alternative phenotypes more favorable to the tumor microenvironment, effectively disarming the immune response.

Using a combination of single-cell RNA sequencing, chromatin accessibility profiling, and functional assays, the investigators tracked shifts in B cell populations in tumor-bearing mice and human pancreatic cancer samples. They observed marked heterogeneity emerging within the B cell compartment, with subsets losing canonical B cell markers while gaining characteristics typical of myeloid or regulatory phenotypes. This transdifferentiation is critical because it converts B cells from potential anti-tumor effectors into cells that promote immune tolerance and tumor progression.

The implications of these findings are profound. By co-opting B cell lineage plasticity, pancreatic tumors cultivate an immunosuppressive niche that blunts cytotoxic T cell activity and facilitates immune escape. This adds to the growing body of evidence pointing to the tumor microenvironment’s complexity and the multifaceted roles of immune cells beyond their classical functions. Targeting the Pax5 pathway or its downstream effectors might thus represent a promising therapeutic strategy to restore effective anti-tumor immunity in pancreatic cancer patients.

Notably, this study expands the paradigm beyond T cell-centric immunotherapies, underscoring the necessity to consider B cell dynamics and lineage stability in cancer treatment design. Current checkpoint inhibitors have shown limited efficacy in pancreatic cancer, partly due to the highly immunosuppressive milieu. Interventions aimed at stabilizing Pax5 expression or preventing B cell transdifferentiation could synergize with existing immunotherapies to overcome resistance.

Additionally, the researchers highlighted the plasticity of B cells as a dynamic process, influenced by extrinsic signals from the tumor microenvironment including cytokines, metabolic cues, and direct cellular interactions. These factors collectively orchestrate a transcriptional reprogramming landscape that dismantles the B cell identity. Understanding these upstream signals could help identify early biomarkers of immune dysfunction and guide the development of targeted therapies that modulate the microenvironment.

Moreover, the study’s approach integrates cutting-edge technology, including chromatin immunoprecipitation sequencing (ChIP-seq) for Pax5 binding sites and fate-mapping models, which provide causal evidence linking Pax5 inhibition to phenotypic shifts. This comprehensive methodology lends robustness to the conclusions and opens doors for similar investigations across other malignancies where immune evasion remains a challenge.

The evidence of B cell lineage plasticity challenges the previously held dogma that immune cells are terminally differentiated once committed. Instead, it presents a nuanced view where immune cells dynamically adapt their identity in pathological contexts, with consequences for disease progression and therapy response. This newfound plasticity emphasizes the need to revisit fundamental immunological concepts and their application in oncology.

Clinically, these insights could translate into novel diagnostic tools to stratify pancreatic cancer patients by the degree of immune evasion orchestrated via B cells. Monitoring Pax5 levels or the emergence of atypical B cell subsets in blood or tumor biopsies might serve as indicators for prognosis and therapeutic responsiveness, fostering more personalized treatment strategies.

Further research is warranted to delineate the downstream pathways activated upon Pax5 suppression and how these contribute to the immunosuppressive phenotype. For instance, identifying key cytokines secreted by transdifferentiated B cells or the molecular crosstalk with other immune cells would provide a more comprehensive understanding of tumor-immune interactions.

In summary, this pioneering work illuminates a critical mechanism of pancreatic cancer immune subversion through transcription factor-mediated B cell plasticity. The discovery that Pax5 inhibition fosters B cell lineage reprogramming to sustain immunosuppression significantly advances the field of tumor immunology, with promising implications for developing novel immunotherapeutic approaches tailored to combat pancreatic cancer’s formidable resistance.

As pancreatic cancer continues to pose significant clinical challenges due to late diagnosis and poor response to existing treatments, such molecular insights offer a beacon of hope. By targeting the immune system’s intrinsic plasticity and its hijacking by the tumor, future therapies might finally turn the tide against this devastating disease, improving survival and quality of life for patients worldwide.

The study exemplifies the power of interdisciplinary research combining molecular biology, immunology, and advanced genomics to unravel cancer’s complex biology. It underscores the critical importance of continuing to decode tumor-immune dynamics at the cellular and molecular levels to innovate effective, next-generation cancer therapies.

Subject of Research:
Pancreatic cancer-mediated immune evasion via transcription factor Pax5 inhibition inducing B cell lineage plasticity.

Article Title:
Pancreatic cancer induces B cell lineage plasticity via Pax5 inhibition to sustain immunosuppression.

Article References:
Kassem, A., Naser Al Deen, N., Yifeng, S. et al. Pancreatic cancer induces B cell lineage plasticity via Pax5 inhibition to sustain immunosuppression. Cell Death Discov. 12, 265 (2026). https://doi.org/10.1038/s41420-026-03174-z

Image Credits: AI Generated

DOI: 02 June 2026

Regulatory T cells play a critical role in maintaining immune homeostasis, preventing the immune system from overreacting and causing damage to healthy tissues. However, within the hostile environment of lung tumors, these cells are co-opted to perform an opposite role: shielding the tumor from immune attack. The researchers focused their investigation on non-small cell lung cancer (NSCLC), the most common and deadly subtype of lung cancer globally. They discovered that Tregs within lung tumors express elevated levels of the purinergic receptor P2RX7, a molecule integral to cellular sensing of extracellular ATP, a danger signal abundant in tumors.

Extracellular ATP, released by stressed or dying cells, is prevalent in tumor microenvironments due to hypoxia and metabolic disturbances characteristic of aggressive cancers. Normally, ATP serves as a distress beacon that activates immune responses. However, the high expression of P2RX7 on Tregs endows these cells with the ability to detect and exploit this ATP-rich milieu. When activated by ATP, P2RX7 prompts Tregs to accumulate in the tumor, heightening their suppressive functions against cytotoxic immune cells that would otherwise recognize and destroy cancer cells.

This discovery is pivotal because it links P2RX7 signaling directly to immune suppression within lung tumors. By studying patient-derived data, the investigators identified a strong correlation between elevated P2RX7 expression on intratumoral Tregs and poor survival outcomes, suggesting that this pathway plays a significant role in tumor progression. The prolonged activity of Tregs dampens the immune surveillance that is vital for controlling tumor growth, effectively providing cancer cells a shield against immunological eradication.

Further mechanistic studies demonstrated that removal of P2RX7 from Tregs slows lung tumor growth. In experimental models where P2RX7 was genetically deleted in these cells, the tumors exhibited reduced size and burden. This deceleration was attributed to a reinvigoration of anti-tumor immune responses, as effector T cells, particularly CD8+ cytotoxic lymphocytes, were better able to infiltrate the tumor and perform their destructive functions. The absence of P2RX7 on Tregs resulted in diminished suppressive capacity, restoring a more balanced immune environment conducive to tumor clearance.

A key molecular mediator influenced by P2RX7 activity is CTLA-4, an immune checkpoint molecule renowned for its role in attenuating immune responses. The study revealed that signaling through P2RX7 in Tregs upregulates CTLA-4 expression, further consolidating their ability to quench effector immune cells. Without P2RX7, Tregs produce less CTLA-4, thereby weakening their immunosuppressive grip within the tumor microenvironment. This insight suggests that P2RX7 works upstream of well-known checkpoint pathways, positioning it as a master regulator of immune suppression in lung cancer.

Intriguingly, the researchers found that inhibition of P2RX7 not only affects Tregs but also fosters a more collaborative immune microenvironment by promoting interactions between T cells and B cells within tumors. This collaboration leads to the formation of tertiary lymphoid structures (TLS), highly organized lymphoid aggregates that resemble lymph nodes and are associated with improved clinical outcomes. The presence of these immune cell clusters correlates with heightened antibody production directed at tumor antigens, contributing additional layers of immune attack against cancer cells.

Capitalizing on these insights, the Mayo Clinic team evaluated a pharmacologic inhibitor of P2RX7 in preclinical lung cancer models. The inhibitor effectively reduced tumor growth, decreased the number of regulatory T cells within tumors, and revitalized overall immune functionality. While this drug is not yet approved for clinical use in cancer, the promising results lay the groundwork for future translational studies and potential combination therapies with existing immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies.

This research presents a paradigm shift in understanding immune evasion by lung tumors, highlighting the sophisticated strategies tumors employ to subvert normal immune regulatory pathways. By effectively ‘hijacking’ Tregs through P2RX7-mediated sensing of extracellular ATP, lung cancers create a microenvironment that thwarts immune system attacks. Targeting this axis may overcome one of the major hurdles in lung cancer immunotherapy, expanding effective treatment to a broader patient population currently unresponsive to therapy.

The authors emphasize that while these findings illuminate a critical mechanism of immune suppression in lung cancer, further research is required to translate these preclinical results into effective clinical treatments. Future studies will aim to refine P2RX7 inhibitors, evaluate their safety and efficacy in human trials, and explore synergistic effects with other immunomodulatory agents. Ultimately, this work underscores the importance of dissecting tumor-immune interactions at a molecular level to devise novel strategies capable of enhancing the immune system’s ability to combat cancer.

Lung cancer remains the leading cause of cancer mortality worldwide, with immunotherapy offering a beacon of hope yet delivering durable responses in only a subset of patients. This new discovery positions P2RX7 as a promising therapeutic target that could amplify the effectiveness of immunotherapies, unleashing previously restrained immune cells to fully engage and eliminate malignant cells. The intricate connection between ATP sensing, Treg function, and tumor progression offers a compelling narrative that could reshape lung cancer treatment paradigms in the years to come.

In summary, the Mayo Clinic study reveals that lung tumors exploit regulatory T cells’ P2RX7-mediated sensing of extracellular ATP to accumulate these suppressive cells and enhance their immune-inhibitory functions. By blocking P2RX7, the immune system’s anticancer capabilities are restored, slowing tumor growth and promoting beneficial immune cell interactions within tumors. These findings open exciting avenues for developing novel treatments aimed at dismantling tumor-induced immune suppression and improving outcomes for patients battling lung cancer.

Subject of Research:
The role of P2RX7-mediated ATP sensing by regulatory T cells in immune suppression and lung tumor growth.

Article Title:
Regulatory T-cell sensing of extracellular ATP via P2RX7 promotes their accumulation and suppression and drives lung tumor growth

News Publication Date:
21-Jan-2026

Web References:
https://www.mayoclinic.org
https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-25-0567/771882/Regulatory-T-cell-sensing-of-extracellular-ATP-via

References:
Borges da Silva, H., et al. (2026). Regulatory T-cell sensing of extracellular ATP via P2RX7 promotes their accumulation and suppression and drives lung tumor growth. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.CIR-25-0567

Keywords:
Lung cancer, regulatory T cells, immunotherapy resistance, P2RX7, extracellular ATP, immune suppression, CTLA-4, tumor microenvironment, immunotherapy enhancement, tertiary lymphoid structures, immune checkpoint, Mayo Clinic